Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05356403




Registration number
NCT05356403
Ethics application status
Date submitted
18/04/2022
Date registered
2/05/2022
Date last updated
7/05/2024

Titles & IDs
Public title
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension
Secondary ID [1] 0 0
CR845-310302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Diseases 0 0
Pruritus 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Difelikefalin 1 mg Oral Tablet
Treatment: Drugs - Placebo Oral Tablet

Experimental: Difelikefalin 1 mg Oral Tablet - Patients receive oral difelikefalin 1 mg once daily

Placebo Comparator: Placebo Oral Tablet - Patients receive oral placebo once daily


Treatment: Drugs: Difelikefalin 1 mg Oral Tablet
Difelikefalin 1 mg medication taken orally 1 time/day

Treatment: Drugs: Placebo Oral Tablet
Placebo tablet taken orally 1 time/day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects achieving at least a 4-point improvement from baseline with respect to the weekly mean of the daily 24-hour WI-NRS score at Week 12 of Treatment Period 1
Timepoint [1] 0 0
Week 12 of Treatment Period 1
Secondary outcome [1] 0 0
Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects achieving at least a 4-point improvement from baseline with respect to the weekly mean of the WI-NRS at Week 8 of Treatment Period 1.
Timepoint [1] 0 0
Week 8 of Treatment Period 1
Secondary outcome [2] 0 0
Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects achieving at least a 4-point improvement from baseline with respect to the weekly mean of the WI-NRS at Week 4 of Treatment Period 1.
Timepoint [2] 0 0
Week 4 of Treatment Period 1
Secondary outcome [3] 0 0
Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects who are "complete itch responders" defined as subjects with = 70% of the non-missing 24-hour WI-NRS scores equal to 0 or 1 at Week 12 of Treatment Period 1.
Timepoint [3] 0 0
Week 12 of Treatment Period 1
Secondary outcome [4] 0 0
Efficacy Assessment Phase (Treatment Period 1): Change from baseline in Sleep Quality Questionnaire score at the end of Week 12 of Treatment Period 1.
Timepoint [4] 0 0
Week 12 of Treatment Period 1

Eligibility
Key inclusion criteria
To be eligible for inclusion into the study, a patient must meet the following criteria:

- Advanced stage 4 and 5 CKD and end stage renal disease on hemodialysis

- Subject self-reports experiencing at least near-daily (eg, most days of a week)
pruritus for at least 6 months prior to screening.

- Inadequate response to current or prior treatments (including emollients/moisturizers,
topical medications, or systemic treatments) for pruritus prior to screening.

Prior to randomization on Day 1 of Treatment Period 1:

1. Has recorded at least 4 WI-NRS scores during the 7-day Run-in Period; and

2. Has a mean baseline WI-NRS score = 5, defined as the average of all non-missing scores
reported during the 7-day Run-in Period.
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A patient will be excluded from the study if any of the following criteria are met:

- Scheduled to receive a renal replacement therapy (dialysis or kidney transplant)
during the study.

- Has a concomitant disease, significant medical condition or
physical/laboratory/ECG/vital signs abnormality that, in the opinion of the
investigator, puts the subject at undue risk or interferes with interpretation of
study results, impedes completion of the study procedures, or compromises the validity
of the study measurements.

- New or change of treatment received for itch, including antihistamines and
corticosteroids (oral, intravenous, or topical), within 14 days prior to the start of
run-in.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/02/2024
Sample size
Target
Accrual to date
Final
105
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Cara Therapeutics Study Site - Adelaide
Recruitment hospital [2] 0 0
Cara Therapeutics Study Site - Camperdown
Recruitment hospital [3] 0 0
Cara Therapeutics Study Site - Concord
Recruitment hospital [4] 0 0
Cara Therapeutics Study Site - Gosford
Recruitment hospital [5] 0 0
Cara Therapeutics Study Site - Kogarah
Recruitment hospital [6] 0 0
Cara Therapeutics Study Site - Launceston
Recruitment hospital [7] 0 0
Cara Therapeutics Study Site - Liverpool
Recruitment hospital [8] 0 0
Cara Therapeutics Study Site - Melbourne
Recruitment hospital [9] 0 0
Cara Therapeutics Study Site - Saint Albans
Recruitment hospital [10] 0 0
Cara Therapeutics Study Site - Westmead
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Camperdown
Recruitment postcode(s) [3] 0 0
- Concord
Recruitment postcode(s) [4] 0 0
- Gosford
Recruitment postcode(s) [5] 0 0
- Kogarah
Recruitment postcode(s) [6] 0 0
- Launceston
Recruitment postcode(s) [7] 0 0
- Liverpool
Recruitment postcode(s) [8] 0 0
- Melbourne
Recruitment postcode(s) [9] 0 0
- Saint Albans
Recruitment postcode(s) [10] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
South Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
Argentina
State/province [7] 0 0
Ciudad Autonoma de Buenos Aire
Country [8] 0 0
Argentina
State/province [8] 0 0
Corrientes
Country [9] 0 0
Argentina
State/province [9] 0 0
Lanús
Country [10] 0 0
Argentina
State/province [10] 0 0
Mar Del Plata
Country [11] 0 0
Argentina
State/province [11] 0 0
San Nicolás
Country [12] 0 0
Argentina
State/province [12] 0 0
Sarandí
Country [13] 0 0
Brazil
State/province [13] 0 0
Belo Horizonte
Country [14] 0 0
Brazil
State/province [14] 0 0
Joinville
Country [15] 0 0
Brazil
State/province [15] 0 0
Salvador
Country [16] 0 0
Brazil
State/province [16] 0 0
São Bernardo Do Campo
Country [17] 0 0
Brazil
State/province [17] 0 0
São José Do Rio Preto
Country [18] 0 0
Brazil
State/province [18] 0 0
São Paulo
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Dobrich
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Gabrovo
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Montana
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Germany
State/province [23] 0 0
Heilbronn
Country [24] 0 0
Germany
State/province [24] 0 0
Kaiserslautern
Country [25] 0 0
Hungary
State/province [25] 0 0
Baja
Country [26] 0 0
Hungary
State/province [26] 0 0
Budapest
Country [27] 0 0
Hungary
State/province [27] 0 0
Kistarcsa
Country [28] 0 0
Hungary
State/province [28] 0 0
Pécs
Country [29] 0 0
Italy
State/province [29] 0 0
Firenze
Country [30] 0 0
Italy
State/province [30] 0 0
Modena
Country [31] 0 0
Italy
State/province [31] 0 0
Pavia
Country [32] 0 0
Italy
State/province [32] 0 0
Roma
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Daegu
Country [34] 0 0
Korea, Republic of
State/province [34] 0 0
Goyang-si
Country [35] 0 0
Korea, Republic of
State/province [35] 0 0
Seoul
Country [36] 0 0
Mexico
State/province [36] 0 0
Aguas Calientes
Country [37] 0 0
Mexico
State/province [37] 0 0
Durango
Country [38] 0 0
Mexico
State/province [38] 0 0
Guadalajara
Country [39] 0 0
Mexico
State/province [39] 0 0
Mérida
Country [40] 0 0
Poland
State/province [40] 0 0
Golub-Dobrzyn
Country [41] 0 0
Poland
State/province [41] 0 0
Katowice
Country [42] 0 0
Poland
State/province [42] 0 0
Kraków
Country [43] 0 0
Poland
State/province [43] 0 0
Szczecin
Country [44] 0 0
Poland
State/province [44] 0 0
Wroclaw
Country [45] 0 0
Poland
State/province [45] 0 0
Lódz
Country [46] 0 0
Romania
State/province [46] 0 0
Bucharest
Country [47] 0 0
Romania
State/province [47] 0 0
Oradea
Country [48] 0 0
Romania
State/province [48] 0 0
Timisoara
Country [49] 0 0
Spain
State/province [49] 0 0
Almería
Country [50] 0 0
Spain
State/province [50] 0 0
Badalona
Country [51] 0 0
Spain
State/province [51] 0 0
Barcelona
Country [52] 0 0
Spain
State/province [52] 0 0
Ferrol
Country [53] 0 0
Spain
State/province [53] 0 0
Madrid
Country [54] 0 0
Spain
State/province [54] 0 0
Palma De Mallorca
Country [55] 0 0
Spain
State/province [55] 0 0
Valencia
Country [56] 0 0
Spain
State/province [56] 0 0
Vitoria

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cara Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared
to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD)
patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment
Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind
12-week Treatment Period (Treatment Period 1), and the Long-term Extension Phase includes a
double-blind Treatment Period (Treatment Period 2) of up to 52 weeks.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05356403
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Cara Therapeutics, PhD
Address 0 0
Cara Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05356403